



# Sedative/Hypnotics

*Fall, 2017 by Dr . ISAM AI NASER*

*Authors FRANK A. BARILE*

# INTRODUCTION

- Sedative-hypnotic drugs are used therapeutically to produce **facilitate sleep**.
- A variety of these agents have been developed over the **past century**, each with adverse effects, **toxicity**, and problems with **tolerance as well as drug withdrawal**.
- **Chloral hydrate** and the **bromides**, popular sedatives before 1900, were replaced by the **barbiturates** at the turn of the twentieth century. Recognition of the **abuse** potential of barbiturates led to the development of newer pharmacologic agents .


Most of these drugs, which include **chloral hydrate and meprobamate.**, either have been **withdrawn from the market** are prescribed **very infrequently** **toxicity** and **abuse potential**.

The **benzodiazepines** were marketed **as safe** and **non addictive sedative** and **anxiolytic agents** but now are recognized as having significant potential for **dependence**.

- Today, the most popular therapeutic agents for **anxiety**(used for sedation),
- **hypnosis** (used for sleep), or
- a **naesthesia** for deep sleep include **Buspirone and Zolpiden**.
- Benzodiazepines are still frequently employed.
- **Barbiturates** are still the cause of 50,000 accidental and intentional poisonings per year, and their synergistic effects with ethanol are one of the leading causes of hospital admissions.

# Barbiturates

- **Medicinal Chemistry** are malonylurea derivatives, synthesized from malonic acid and urea.
- The electron negative carbonyl give an acidic nature to the molecule, this classifying them as weak acids.





# Pharmacology and Clinical Use

- Barbiturates are traditionally classified as long, intermediate, short, and ultra-short acting based on the duration of action of a single dose in rabbits .
- The major action is the production of sedation. Hypnosis, or anesthesia **through CNS depression** .
- for instance, a 100 mg dose of secobarbital ingested in the home at bedtime to induce sleep would, most likely, only cause a mild euphoria in habitual user without significant sedation.

The effect depends largely on

- dose,
- mental status of patient
- duration of action of the drug,
- tolerance of the individual to this class of drugs.
- These factors determine the **therapeutic** or **euphoric** response.

# Toxicokinetics and Metabolism

An increase in the number of **carbons side chains** results in **enhanced** lipid solubility, with corresponding increase **in toxicity**.

Replacement of the **C2** with **sulfur group** as with (**thiopental**) decreases its electron negativity, making it **less acidic, more lipid soluble**.

**R1-ethyl and phenyl-** most polar side chains, **slowest onset and longest duration**.

Thus *phenobarbital enters the CNS very slow as compared* to the more **lipophilic thiopental**.



# Properties of barbiturates

## Properties of Barbiturates

| Compounds <sup>a</sup>    | R <sub>1</sub>          | Classification | Sedative/Hypnotic<br>Dose (Total mg Daily) | Toxic Concentration<br>(mg/dl) | t <sub>1/2</sub> (h) | pKa |
|---------------------------|-------------------------|----------------|--|--------------------------------|----------------------|-----|
| Barbital                  | ethyl                   | LA             | 100–200/300–500                            | 6–8                            | —                    | 7.8 |
| Phenobarbital             | phenyl                  | LA             | 30–90/100–200                              | 4–6                            | 24–140               | 7.2 |
| Amobarbital               | isopentyl               | IA             | 30–150/100–200                             | 1–3                            | 8–42                 | 7.8 |
| Pentobarbital             | 1-mb                    | SA             | 20–150/100                                 | 0.5–1.0                        | 16–48                | 7.9 |
| Secobarbital <sup>b</sup> | 1-mb                    | SA             | 30–200/100                                 | 0.5–1.0                        | 20–34                | 7.9 |
| Thiopental                | 1-mb, C <sub>2</sub> =S | UA             | 3–5 mg/kg                                  | <0.5                           | <1                   | 7.4 |

*Note:* R<sub>1</sub> = side group substitutions corresponding to Figure 11.1; 1-mb = 1-methylbutyl; LA = long-acting, IA = intermediate-acting, SA = short-acting, UA = ultrashort-acting.

<sup>a</sup> Grouped according to classification.

<sup>b</sup> The ethyl group for secobarbital is replaced by an allyl side chain.

# Mechanism of Toxicity

- **CNS depression** accounts for all of barbiturate poisoning.
- The drugs bind to an **allosteric** site on the GABA-Cl<sub>2</sub> receptor, an inhibitory neurotransmitter, in **presynaptic** or **postsynaptic** neuronal terminals in the CNS.
- Positive modulation of the action of (GABA<sub>A</sub>) at receptors –anxiolytic, -sedative, hypnotics, -general anesthetics, - anticonvulsants.

- At higher doses, barbiturates **depress medullary respiratory** centers. resulting in inhibition of respiratory function.
- Barbiturates **decrease postsynaptic depolarization** by acetylcholine , due to **postsynaptic block**, resulting in **smooth, skeletal, and cardiac muscle depression**.

# Signs and symptoms of Acute Toxicity

- Clinical signs and symptoms are more reliable indicators of clinical toxicity than plasma concentration.
- CNS depression of Barbiturates, does not correlate with plasma **concentration**.
- CNS effects include anticonvulsant, anesthetic, anxiolytic, and sedative-hypnotic actions.
- In particular, the **hypoxic drive** for respiration is sensitive to barbiturates.
- **Doses only three times greater than the usual hypnotic dose have been shown to depress respiratory drive.**

At the highest doses -hypotension , bradycardia, and decreased cardiac output.

**Respiratory acidosis** results from accumulation of carbon dioxide , **shifting pH balance to the formation of carbonic acid.**

The condition **resembles alcoholic inebriation** as the patient presents with **hypoxic shock, rapid pulse, cold and sweaty skin, and slow or rapid, breathing.**



- Delayed complications of acute renal failure, pneumonia, pulmonary edema, and cerebral edema.
- Hypotension, depth of coma, and excess fluid administration as risk factors.

# Clinical management of acute overdoses

- Scandinavian method for symptomatic treatment for CNS depressants.

This includes maintaining the ventilation, keeping the patient warm, supporting vital functions.

Oxygen support, forced diuresis, maintain blood pressure and kidney function.


Multiple doses of activated charcoal (MDAC) have been shown to enhance the non renal clearance of intravenous phenobarbital.

Alkalinization of urine to a pH greater than 7.5 to 8.0 has been shown to enhance elimination of phenobarbital independent of urine flow rate.

Withdrawal syndromes of barbiturates.  
hallucinations, sleeplessness , vertigo, and  
convulsions , depending upon the degree  
of dependency.

# Benzodiazepines

- The Benzodiazepines wide use as **S/H**, **anxiolytic**, anticonvulsants, **preanesthetic** sedatives ,and muscle relaxants.
- **Their increased therapeutic index**, relative to barbiturates, and lack of **anesthetic properties** have promoted the substitution of **benzodiazepines for barbiturates**.



# Medicinal chemistry

All the important benzodiazepine contain a 5-aryl-1,4-benzodiazepine structure.

The chemical nature of substituent's at positions 1 and 3 varies widely.

Their half- life correlates well with their duration of action ,as ell as duration of toxic manifestations.

Structure-activity relationship, however, has failed to correlate the pharmacological and toxicological profiles with the chemical structure.



# Pharmacology and Mechanism of Toxicity

Benzodiazepine bind to all three omega receptor.

Benzodiazepine bind to a allosteric site of the ( $\alpha$ , $\beta$ )GABA Cl<sup>-</sup> ionophore complex.

This action increases the frequency of the opening of the chloride channels.

At last, the drugs enhance the affinity of GABA for receptors.

- The effects of GABA- mediated action account for benzodiazepines S/H, anticonvulsant, and skeletal muscle relaxation properties.
- At high doses, benzodiazepines induce cause vasodilation and hypotension .
- The compound do not much change ventilation, except the elderly population, and the presence of alcohol or other S/H.
- There is also minimal effect on cardiovascular .

# Properties of benzodiazepines

TABLE 112

Properties of Benzodiazepines

| Generic Name <sup>a</sup> | Proprietary Name | Classification                      | Sedative/Hypnotic Total Daily Dosage (mg) | Toxic Concentration  | t <sub>1/2</sub> (h) |
|---------------------------|------------------|-------------------------------------|---|----------------------|----------------------|
| Alprazolam                | Xanax            | Anxiolytic                          | 0.25–1.5/0.5–1.0                          | 0.4 µg/dl            | 12–19                |
| Chlordiazepoxide          | Librium          | Anxiolytic                          | 5–100/25–50                               | 3.5–10 mg/l          | 7–28                 |
| Clorazepate               | Tranxene         | Anxiolytic-S/H                      | 3.75–22.5/7.5–15                          | —                    | 30–60                |
| Diazepam                  | Valium           | Anxiolytic-S/H, SKR, anticonvulsant | 2–40/5–10                                 | 0.5–2.0 mg/dl        | 20–90                |
| Flurazepam                | Dalmane          | Hypnotic                            | —/15–30                                   | 0.25 mg/dl           | 24–100               |
| Lorazepam                 | Ativan           | Anxiolytic-S/H, anticonvulsant      | 0.5–3.0/2–4                               | 0.3 µg/dl            | 10–20                |
| Oxazepam                  | Serax            | Anxiolytic-S/H                      | 10–120/10–30                              | 3–5 mg/l             | 5–10                 |
| Temazepam                 | Restoril         | S/H                                 | —/7.5–30                                  | 1.0 mg/l             | 9–12                 |
| Triazolam                 | Halcion          | Anxiolytic-S/H                      | 0.25–1.5/0.125–0.5                        | 7 µg/kg (toxic dose) | 2–3                  |

*Note:* S/H = sedative/hypnotic; SKR = skeletal muscle relaxant.

<sup>a</sup> Grouped by generic name.

# Toxicokinetics

- All of benzodiazepines are **completely absorbed**, primarily due to their **high nonionic/ionic ratio**.
- **Lipophilicity, polarity and electron negativity** *different* by the various substituent's.

# Signs and Symptoms of Acute Toxicity

In general, nonspecific, apparent toxicity depends on the extent of intoxication.

Serum toxic concentration of benzodiazepines do not correlate well with signs and symptoms.

Mild toxicity is characterized by ataxia, drowsiness, and motor incoordination.

In moderate toxicity, the patient is aroused by verbal stimulation, although may enter coma stage one or two.

In severe toxicity are unresponsive except to deep pain stimulation, consistent with coma.

In general, respiratory depression and hypotension are rare.



# Clinical Management of Acute Overdose

Clinical management is symptomatic, and also specific antidote. **Flumazenil**, a 1,4-imidazobenzodiazepine, is a benzodiazepine antagonist.

Flumazenil completely **reverses** the **sedative, anticonvulsant**, ataxic, anesthetic, comatose, and muscle relaxant effects.

Administration of 0,2to 1,0 mg i.v.

Has an acute start of 1 to 3 min and a peak effect at 6 to 10 min.

# Tolerance and withdrawal.


The withdrawal syndrome depending on the dose.

As with barbiturate and alcohol, benzodiazepine withdrawal signs and symptoms are similar.

hallucinations, sleeplessness, vertigo, and convulsions, depending upon the degree of dependency.

# Misellaneous sedative/hypnotics

- Chloral hydrate
- Mepromate
- Zolpidem tartrate
- Buspirone
- Flunitazepam
- GHB (Gamma-Hydroxybutyrate).



# Chloral Hydrate

Although it has no analgesic effect, and more effective, **less toxic drug are available, as S/H.**

Available in **Oral liquid dosage forms only**, the compound is **lipid soluble**.

The long acting metabolite of chloral hydrate, **Trichloroethanol**, is responsible for most its **toxicity**, its low therapeutic index, and its **undetectable** presence in plasma.


# Sings and symptoms of toxicity

CNS depression, ataxia, gastrointestinal irritation, cardiovascular instability, and proteinuria.


An **increased risk of sudden death** with chloral hydrate intoxication is a **result of development arrhythmias**.

Chloral hydrate has been implicated as a **carcinogen**, this finding remains controversial.





# Meprobamate




A propanediol carbamate derivative.

is marketed as an alternative S/N to barbiturates.

Toxicity is similar to that of the barbiturates, including the production of **ataxia and coma**.

**Chronic use** of the drug has been associated with severe hematopoietic disturbances such as **aplastic anemia** and **thrombocytopenia**.



# Flunitrazepam

Is used in treatment of **insomnia** and **anesthetic** as benzodiazepine.

The tablets are **tasteless**, **odorless**, **relatively inexpensive**, **dissolve rapidly in alcohol**, and are easily administered **by intranasal or oral**.

Department of justice [**drug-facilitated rape**].

The victim of a drug –facilitated sexual assault may exhibit signs of confusion, **memory loss**, drowsiness, **slurred speech** and uninhibited behavior.

- The flunitrazepam causes euphoria, hallucinations and used to enhance heroin and cocaine euphoria.
- It is highly lipid soluble, with a quick onset (20-30min) And a duration of up to 12 h.

It affects GABA receptors with a potency of up to ten times that of diazepam.

as a result ,drowsiness, disorientation, and dizziness (DDD), slurred speech, respiratory depression and coma.

**Treatment** is supportive, with respiratory maintenance of primary importance (ABC) (maintain airway , breathing and circulation).

**Flumazenil** is used as an antidote for respiratory depression.

# GHB(gamma-hydroxybutyrate)

- Since its synthesis in 1960 GHB has been **abused for sleep disorders** , as an **anesthetic agent** , as treatment for alcohol and opiate and an **aphrodisiac**.
- The tasteless ,odorless, liquid or gel, use as a date –rape drug.
- GHB interacts with GABA-b receptors, as well as opioid receptors, depressed CNS
- It has a quick onset (15-30 min) and relatively short duration. 3 h.

Ingestion of GHB in an alcoholic drink by victim, causes hallucinations and amnesia, as well as symptoms not unlike flunitrazepam.

At higher doses in absence of alcohol ,its toxicity outweighs the euphoric effects.

Within 15 min of ingestion , the apnea ,hypoxia and vomiting, respiratory depression,bradycardia, muscular contraction ,decreased cardiac output, amnesia and coma

*Apnea:* انقطاع التنفس

*Amnesia:* فقدان الذاكرة

*Outweighs:* أكثر أهمية



- As flunitrazepam, treatment of GHB toxicity is supportive, with respiratory maintenance of primary importance(ABC)
- Withdrawal symptoms are important.  
Anxiety attacks, and increased blood pressure a few hours after the last dose.

*Anxiety attacks: نوبة قلق*

# Buspirone

Buspirone is an antianxiety agent that is not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other S/H drugs.

It does not exert anticonvulsant or muscle relaxant effects, nor does it interact with GABA receptors.

Instead, it has high affinity for serotonin (5-HT<sub>1A</sub>) and dopamine (D<sub>2</sub>) receptors.

# Buspirone

- Overdoses of up to 150 times the average anxiolytic dose (approximately 3 g) have not been associated with lasting untoward effects.

- In addition, additive effects with ethanol are minimal.

It has not been associated with the production of dependence or withdrawal,

- unlike the barbiturates and benzodiazepines, buspirone is not a federally controlled substance.

# Methods of detection

- Urine screening is useful for detecting many criminal drugs except flunitrazepam, which requires specific analysis.
- Because of their short half-life and low concentrations, most commercially available toxicology screens (immunoassays) are unable to detect flunitrazepam.
- The most definitive detection of flunitrazepam is GC-MS.

The **immunoassays**, enzyme-multiplied immunoassay technique (**EMIT**) and radioimmunoassay(**RIA**), are designed to identify unmetabolized barbitol in the urine.

**Positive tests for phenobarbital** have been noted in chronic users up to **several weeks after discontinuation**.

**TLC,GC,GC/ID, GC/MS,HLPC**